Downloaded from http://jcp.bmj.com/ on November 14, 2015 - Published by group.bmj.com
Original article
Preoperative serum-gamma-glutamyltransferase (GGT) does not represent an independent prognostic factor in a European cohort of patients with non-metastatic renal cell carcinoma Orietta Dalpiaz,1 Martin Pichler,2,3 Edvin Mrsic,1 Daniel Reitz,2 Daniel Krieger,1 Luca Venturino,1 Angelika Bezan,2 Tatjana Stojakovic,4 Karl Pummer,1 Richard Zigeuner,1 Georg C Hutterer1 ▸ Additional material is published online. To view please visit the journal (http:// dx.doi.org/10.1136/jclinpath2014-202683) 1
Department of Urology, Medical University of Graz, Graz, Austria 2 Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria Correspondence to Dr Martin Pichler, Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz A-8036, Austria; [email protected] Received 25 September 2014 Revised 18 March 2015 Accepted 22 March 2015 Published Online First 10 April 2015
ABSTRACT Aims Increasing evidence suggests that the serumgamma-glutamyltransferase (GGT) might correlate with tumour development and growth rates in various human cancer types. Thus, we decided to investigate the potential prognostic impact of the preoperatively assessed serum-GGT in a European cohort of patients with non-metastatic renal cell carcinoma (RCC). Methods Clinicopathological data from 700 consecutive patients with non-metastatic RCC, operated between 2000 and 2010 at a single tertiary academic centre, were evaluated retrospectively. Preoperative serum-GGT was assessed 1 day before surgery. Patients were categorised using a serum-GGT cut-off value of 40 U/L according to a calculation by receiver operating curve analysis. Patients’ cancer-specific survival (CSS), metastasis-free survival (MFS), as well as overall survival (OS) were assessed using the Kaplan-Meier method and Cox proportional models. Results In univariate analysis, an elevated preoperative serum-GGT level (
Original article
Preoperative serum-gamma-glutamyltransferase (GGT) does not represent an independent prognostic factor in a European cohort of patients with non-metastatic renal cell carcinoma Orietta Dalpiaz,1 Martin Pichler,2,3 Edvin Mrsic,1 Daniel Reitz,2 Daniel Krieger,1 Luca Venturino,1 Angelika Bezan,2 Tatjana Stojakovic,4 Karl Pummer,1 Richard Zigeuner,1 Georg C Hutterer1 ▸ Additional material is published online. To view please visit the journal (http:// dx.doi.org/10.1136/jclinpath2014-202683) 1
Department of Urology, Medical University of Graz, Graz, Austria 2 Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria Correspondence to Dr Martin Pichler, Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz A-8036, Austria; [email protected] Received 25 September 2014 Revised 18 March 2015 Accepted 22 March 2015 Published Online First 10 April 2015
ABSTRACT Aims Increasing evidence suggests that the serumgamma-glutamyltransferase (GGT) might correlate with tumour development and growth rates in various human cancer types. Thus, we decided to investigate the potential prognostic impact of the preoperatively assessed serum-GGT in a European cohort of patients with non-metastatic renal cell carcinoma (RCC). Methods Clinicopathological data from 700 consecutive patients with non-metastatic RCC, operated between 2000 and 2010 at a single tertiary academic centre, were evaluated retrospectively. Preoperative serum-GGT was assessed 1 day before surgery. Patients were categorised using a serum-GGT cut-off value of 40 U/L according to a calculation by receiver operating curve analysis. Patients’ cancer-specific survival (CSS), metastasis-free survival (MFS), as well as overall survival (OS) were assessed using the Kaplan-Meier method and Cox proportional models. Results In univariate analysis, an elevated preoperative serum-GGT level (
